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OBJECTIVES We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting
(CABG) and examine the drug’s impact on risks for postoperative transfusions among
patients with non–ST-segment elevation acute coronary syndromes (NSTE ACS).
BACKGROUND Adherence in community practice to American College of Cardiology/American Heart
Association guidelines for clopidogrel use among NSTE ACS patients has not been
previously characterized.
METHODS We evaluated 2,858 NSTE ACS patients undergoing CABG at 264 hospitals participating
in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative.
We examined the patterns of acute clopidogrel therapy and its association with bleeding risks
among those having “early” CABG 5 days and again among those having “late” surgery 5
days after catheterization.
RESULTS Within 24 h of admission, 852 patients (30%) received clopidogrel. In contrast to national
guidelines, 87% of clopidogrel-treated patients underwent CABG 5 days after treatment.
Among those receiving CABG within 5 days of last treatment, the use of clopidogrel was
associated with a significant increase in blood transfusions (65.0% vs. 56.9%, adjusted odds
ratio [OR] 1.36, 95% confidence interval [CI] 1.10 to 1.68) as well as the need for transfusion
of 4 U of blood (27.7% vs. 18.4%, OR 1.70, 95% CI 1.32 to 2.19). In contrast, acute
clopidogrel therapy was not associated with higher bleeding risks if CABG was delayed 5
days (adjusted OR 1.18, 95% CI 0.54 to 2.58).
CONCLUSIONS Despite guideline recommendations, the overwhelming majority of NSTE ACS patients
treated with acute clopidogrel needing CABG have their surgery within 5 days of
treatment. A failure to delay surgery is associated with increased blood transfusion require-
ments that must be weighed against the potential clinical and economic impacts of such
delays. (J Am Coll Cardiol 2006;48:281–6) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.029Foundation
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blarge randomized trial has demonstrated that the acute
dministration of clopidogrel—a long-acting antiplatelet
herapy—to patients with non–ST-segment elevation acute
oronary syndromes (NSTE ACS) can reduce subsequent
isk for death, myocardial infarction, or stroke by 20% when
ontinued for a mean duration of nine months (1). How-
ver, single-center case series have demonstrated that, in
From the *Division of Cardiology and the Duke Clinical Research Institute,
urham, North Carolina; †University of North Carolina School of Medicine, Chapel
ill, North Carolina; ‡TIMI Study Group, Brigham and Women’s Hospital, Boston,
assachusetts; §University of Cincinnati College of Medicine, Cincinnati, Ohio;
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and the
Louisiana State University Health Science Center, New Orleans, Louisiana.
RUSADE is a national quality improvement initiative of the Duke Clinical
esearch Institute. CRUSADE is funded by Millennium Pharmaceuticals, Inc. and
chering Corporation. The Bristol-Myers Squibb/Sanofi Pharmaceuticals Partner-
hip provides additional funding support.r
Manuscript received August 30, 2005; revised manuscript received March 17, 2006,
ccepted March 21, 2006.atients requiring coronary artery bypass graft (CABG)
urgery, the use of clopidogrel is associated with increased
isk of perioperative bleeding and a need for transfusion
2–6). This risk appears to be time dependent. For example,
ost-hoc data analysis from the CURE (Clopidogrel in
nstable Angina to Prevent Recurrent Events) trial revealed
hat bleeding risks were increased when patients had CABG
urgery within 5 days of clopidogrel treatment but not when
urgery was delayed for 5 days after treatment with
lopidogrel (1). These findings are reflected in the American
ollege of Cardiology/American Heart Association (ACC/
HA) guidelines for the acute management of patients with
STE ACS, which endorse the acute use of clopidogrel but
lso recommend withholding clopidogrel for at least 5 days
efore CABG surgery (7).
Adherence in community practice to this guidelinesecommendation has not been characterized previously. The
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Clopidogrel and Coronary Artery Bypass Surgery July 18, 2006:281–6urposes of this study were to characterize patterns of
lopidogrel use before CABG and to examine the time-
ependent risks for postoperative transfusion among NSTE
CS patients treated at 264 hospitals participating in the
RUSADE (Can Rapid Risk Stratification of Unstable
ngina Patients Suppress Adverse Outcomes With Early
mplementation of the ACC/AHA Guidelines) National
uality Improvement Initiative (8,9).
ETHODS
atient population. We reviewed the CRUSADE data
rom patients with NSTE ACS who underwent CABG
urgery during their initial hospital stay. Patients with
STE ACS were defined as having ischemic symptoms
ithin 24 h of presentation and either ST-segment depres-
ion, transient ST-segment elevation, or positive cardiac
arkers (elevated troponin I or T and/or creatine
inase-MB greater than the upper limit of normal for
articipating institutions) (8,9). We excluded patients from
ospitals without CABG capabilities; patients who were
ransferred in from other institutions or who were trans-
erred out from the initial institution (because data on
resentation characteristics, acute treatments, clinical out-
omes, and use and timing of invasive procedures were not
vailable for those patients); patients in whom information
n clopidogrel treatment was not available; and those who
eceived transfusion before CABG.
Of a total of 42,156 patients with NSTE ACS admitted
o CABG-capable hospitals, 3,977 (9.4%) underwent
ABG between January 2003 and September 2004 in 264
ospitals participating in the CRUSADE Initiative. After
llowing for the aforementioned exclusions, 2,858 patients
ndergoing CABG constituted the study population for this
nalysis.
ata collection. The institutional review board of each
nstitution approved participation in the CRUSADE Ini-
iative. Data were collected in an anonymous fashion during
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
CABG  coronary artery bypass graft
CI  confidence interval
CRUSADE  Can Rapid Risk Stratification of Unstable
Angina Patients Suppress Adverse
Outcomes With Early Implementation of
the ACC/AHA Guidelines Initiative
CURE  Clopidogrel in Unstable Angina to
Prevent Recurrent Events trial
GP  glycoprotein
NSTE ACS  non–ST-segment elevation acute
coronary syndromes
OR  odds ratio
RBC  red blood cell
RR  relative riskhe initial hospitalization and included baseline clinical gharacteristics, use of acute medications (24 h of hospital
rrival), contraindications to specific therapies, use and
iming of invasive cardiac procedures, laboratory results,
n-hospital clinical outcomes, and discharge therapies and
nterventions.
tatistical analysis. Patients were divided into four groups
or analysis: Specifically, we looked at patients receiving
lopidogrel therapy or not among those going to CABG
early,” i.e., within 5 days of cardiac catheterization. We also
xamined the effects of clopidogrel therapy on outcomes
mong those going to “late CABG” defined as more than 5
ays after catheterization. In these analyses, we conserva-
ively assumed that the use of clopidogrel initiated acutely
as continued until the time of cardiac catheterization but
topped afterwards (when coronary anatomy became known
nd treatment plans for CABG were formulated).
Continuous variables were described using mean or me-
ian values, and categorical variables were described as
ercentages. The Wilcoxon test was used to test for differ-
nces in continuous variables, and the chi-square test was
sed to detect global differences in categorical variables. We
sed generalized estimating equations to determine the
ffect of the use and timing of clopidogrel on the need for
ed blood cell (RBC) transfusions and the number of units
ransfused (10). Both models were adjusted for age, baseline
ematocrit, gender, and signs of congestive heart failure on
resentation. Also, for the need for transfusion outcome, we
djusted for body mass index, previous percutaneous coro-
ary intervention, previous congestive heart failure, renal
nsufficiency, heart rate, and positive cardiac markers. For
he RBC units’ transfused outcome, we adjusted for blood
ressure and hospital region. Race, insurance status, family
istory of coronary artery disease, ST-segment deviation,
iabetes, current/recent smoking, hypercholesterolemia,
revious myocardial infarction, previous stroke, hyperten-
ion, previous CABG, specialty of the caring physician,
vailability of cardiac catheterization laboratories and revas-
ularization procedures, and academic status of the hospital
ere nonsignificant in both models and, thus, no adjust-
ents were made for these variables. Two sets of pair-wise
djusted comparisons were made to examine the effects of
lopidogrel therapy versus not among the “early CABG”
roup (within 5 days) and the “late CABG group” (5
ays). A p value of 0.05 was established as the level of
tatistical significance for all tests. All statistical analyses
ere performed using SAS software (version 8.2, SAS
nstitute, Cary, North Carolina).
ESULTS
f the 2,858 patients in our study, 852 (30%) received
lopidogrel within 24 h of their admission. Of those
atients treated with clopidogrel, 739 (87%) underwent
ABG within 5 days of their last dose of clopidogrel,
hereas the remaining 113 (13%) underwent CABG sur-
ery 5 days after discontinuing clopidogrel. Similarly, the
m
C
g
C
h
r
h
g
c
l
a
t
z
c
c
w
a
S
l
g
t
o
C
g
t
C
s
w
s
f
1
c
w
R
c
1
w
(
a
t
w
t
s
l
O
i
T
A
F
B
W
H
D
O
C
P
P
P
P
P
P
P
R
P
D

onary a
p
283JACC Vol. 48, No. 2, 2006 Mehta et al.
July 18, 2006:281–6 Clopidogrel and Coronary Artery Bypass Surgeryajority of patients not treated with clopidogrel underwent
ABG 5 days of their cardiac catheterization (91%).
The baseline clinical characteristics of the 4 patient
roups are shown in Table 1. Patients who underwent
ABG 5 days with or without clopidogrel had more
igh-risk features, including older age, a history of previous
evascularization, previous stroke, renal insufficiency, and a
igher prevalence of diabetes compared with the respective
roup of patients undergoing early CABG with or without
lopidogrel. Patients with delayed surgery also were more
ikely to present with clinical characteristics associated with
greater risk of adverse outcomes, such as signs of conges-
ive heart failure, higher heart rate, positive cardiac en-
ymes, or severe left ventricular systolic dysfunction. In
ontrast, there were no significant differences between the
linical characteristics and presenting features of patients
ho did not receive clopidogrel and underwent early CABG
nd those who received CABG within 5 days of clopidogrel.
imilarly, there were no significant differences in the base-
ine and presenting clinical features between patients under-
oing late CABG with and without clopidogrel. Although
he use of acute medications was similar in the four groups
f patients, those who received clopidogrel within 5 days of
ABG surgery were more likely to receive intravenous
able 1. Clinical and Hospital Characteristics by Clopidogrel Us
Characteristics
Early CABG <
No Clopidogrel
(n  1,826)
ge (yrs)† 65 (56, 74)
emale gender 28.6
MI (kg/m2)† 28.5 (25, 32)
hite race 84.1
ypertension 68.7
iabetes mellitus 32.2
besity (BMI 30 kg/m2) 38.7
urrent/recent smoker 31.4
revious MI 20.1
revious PCI 13.4
revious CABG 5.0
revious revascularization 17.3
revious CHF 6.0
revious stroke 6.8
eripheral vascular disease 8.6
enal insufficiency‡ 7.2
resenting characteristics
Heart rate (beats/min)† 82 (70, 98)
SBP (mm Hg)† 148 (129, 169)
Hypotension 2.0
ST-segment depression 39.5
Transient ST-segment
elevation
8.6
Positive cardiac markers 87.7
CHF at presentation 18.0
ata presented as percentages except where indicated. *From the time of cardiac cat
2.0 mg/dl, calculated creatinine clearance 30 ml/min, or need for chronic renal d
BMI  body mass index; CABG  coronary artery bypass grafting; CAD  cor
ercutaneous coronary intervention; SBP  systolic blood pressure.lycoprotein (GP) IIb/IIIa inhibitors (Table 2). gThe proportion of patients requiring RBC transfusion in
he four groups is as shown in Table 3. Among the early
ABG group, clopidogrel therapy was associated with a
ignificant increased need for RBC transfusion compared
ith those not receiving clopidogrel. This difference per-
isted after adjusting for differences in baseline clinical
actors between the two groups (adjusted odds ratio [OR]
.36, 95% confidence interval [CI] 1.10 to 1.68). If a higher
utpoint is used, 28% of patients receiving clopidogrel
ithin 5 days of CABG required four or more units of
BCs compared with only 18% of patients not treated with
lopidogrel and undergoing early surgery (adjusted OR
.70, 95% CI 1.32 to 2.19). More patients who had CABG
ithin 5 days of clopidogrel received any platelet transfusion
33.7%) compared with those not treated with clopidogrel
nd undergoing early CABG (22.3%; mean platelet units
ransfused 1.33 vs. 0.76, median 0 in both groups).
In contrast to these results, among those in whom CABG
as delayed 5 days after catheterization, acute clopidogrel
herapy was not associated with increased need for transfu-
ion (adjusted OR 0.81, 95% CI 0.44 to ;1.48) or at risk for
arge transfusions of four or more units of RBCs (adjusted
R 1.18, 95% CI 0.54 to 2.58). No difference was observed
n the need for platelet transfusions in the two late CABG
atients Undergoing CABG
s* Late CABG >5 Days*
lopidogrel
(n  739)
No Clopidogrel
(n  180)
Clopidogrel
(n  113)
5 (56, 74) 68 (60, 75) 67 (59, 76)
30.0 27.8 27.4
.3 (25, 32) 28.8 (26, 33) 28.3 (25, 32)
85.0 76.7 85.0
66.4 71.7 73.5
34.6 35.6 41.6
35.5 40.6 40.7
29.8 35.0 29.2
21.9 23.9 35.4
19.1 14.4 26.6
5.6 5.0 13.3
22.2 17.8 35.4
6.8 16.1 17.7
6.6 8.9 16.8
11.5 13.3 11.5
5.0 10.0 10.6
0 (70, 96) 86 (72, 102) 89 (73, 105)
8 (130, 170) 145 (123, 168) 146 (129, 165)
1.8 3.3 4.4
42.4 37.2 41.6
7.6 15.6 4.4
91.2 88.9 93.8
17.7 25.6 31.0
ation. †Presented as median values with interquartile range. ‡Defined as creatinine
.
rtery disease; CHF  congestive heart failure; MI  myocardial infarction; PCI e in P
5 Day
C
6
28
8
14
heteriz
ialysisroups (Table 3).
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Clopidogrel and Coronary Artery Bypass Surgery July 18, 2006:281–6Death rates generally were low in this population (Table 3).
fter adjusting for baseline clinical factors, there was no
ifference in in-hospital mortality in patients treated with
lopidogrel versus not among those having early CABG
urgery within 5 days of catheterization (adjusted OR 1.31,
5% CI 0.79 to 2.19). Among those undergoing CABG5
ays after catheterization, the in-hospital death rates were
.3% versus 3.9% in the clopidogrel versus no-clopidogrel-
reated patients. The small number of patients in these two
ate CABG groups precluded any multivariable adjust-
ents. Other adjusted outcome measures such as death or
onfatal myocardial infarction, and cardiogenic shock were
lso similar in the two clopidogrel groups compared with
he respective two no-clopidogrel groups. The median
ost-CABG length of stay was also similar in the four
roups.
Because those patients receiving clopidogrel and early
ABG also were more likely to be treated acutely with a GP
Ib/IIIa inhibitor, a factor that may increase the risk for
erioperative bleeding after early CABG (11), we per-
ormed a sensitivity analysis by excluding all patients treated
able 2. Acute Care (24 h) Patterns and In-Hospital Procedur
Characteristics
Early CABG <5 D
No Clopidogrel
(n  1,826)
spirin 94.9
eta-blockers 88.2
eparin—any 92.2
Unfractionated heparin 54.2
LMWH 46.0
P IIb/IIIa inhibitor 39.2
rrival to CABG‡ 69 (40, 104)
umber of diseased vessels
2 22.8
3 72.1
VEF
Moderate (25%–40%) 17.2
Severe (25%) 3.7
ata presented as percentages except where indicated. *Among patients without li
interquartile range).
CABG  coronary artery bypass graft; GP  glycoprotein; LMWH  low mol
able 3. In-Hospital Outcomes by Clopidogrel Use in Patients U
Hospital Outcomes
Early CABG <
No Clopidogrel,
CABG <5 Days
(n  1,826)
Cl
ny RBC transfusion 56.9
BC transfusion 4 U 18.4
BC units transfused† 1.0 (0, 3)
ny platelet transfusion 20.3
eath 2.9
eath or reinfarction 5.7
ardiogenic shock 4.2
troke 1.4
ength of stay (days)† 9.0 (7, 13)
ength of stay post-CABG (days)† 5ata presented as percentages except where indicated. *From the time of cardiac catheteri
CABG  coronary artery bypass graft; RBC  red blood cell.ithin 18 h of surgery with a GP IIb/IIIa receptor antag-
nist. This interval was chosen to be consistent with the
harmacological impact of these agents on bleeding risks
ith surgery. This exclusion had a limited effect on the
esults, as patients receiving clopidogrel and early CABG
ontinued to show an increased risk of requiring RBC
ransfusions compared with the early CABG-no clopidogrel
roup (adjusted OR 1.37, 95% CI 1.08 to 1.75). Similarly,
f we extended our analysis to exclude all patients receiving
P receptor antagonists any time before their CABG, those
eceiving clopidogrel 5 days before CABG continued to
ave a greater need for transfusions compared with the early
ABG-no clopidogrel group (adjusted OR 1.74, 95% CI
.32 to 2.29).
ISCUSSION
ur analysis is the first to provide insight into patterns of
lopidogrel use and outcomes in the setting of CABG
erformed on patients with NSTE ACS. We found that as
any as 30% of patients currently receive clopidogrel before
Clopidogrel Use in Patients Undergoing CABG Surgery*
Late CABG >5 Days†
pidogrel
 739)
No Clopidogrel
(n  180)
Clopidogrel
(n  113)
96.6 90.5 95.5
89.0 87.4 95.2
93.1 92.5 92.0
53.4 59.8 44.6
49.3 45.4 53.6
45.0 36.1 40.8
(44, 104) 193 (162, 236) 203 (164, 251)
27.9 21.5 28.2
65.7 72.9 59.1
16.7 27.7 27.9
3.1 12.7 9.0
ntraindications. †From the time of cardiac catheterization. ‡Presented as median
weight heparin; LVEF  left ventricular ejection fraction.
going CABG Surgery
s* Late CABG >5 Days*
grel <5 Days
re CABG
 739)
No Clopidogrel,
CABG >5 Days
(n  180)
Clopidogrel >5 Days
Before CABG
(n  113)
65.0 67.2 61.1
27.7 26.5 25.7
0 (0, 4) 2 (0, 4) 2.0 (0, 4)
33.7 15.0 17.7
3.5 3.9 5.3
5.0 8.3 6.2
3.8 6.1 4.4
1.6 0.6 1.8
0 (7, 12) 15 (12, 19) 16.0 (13, 20)
6 6 6es by
ays†
Clo
(n
73
sted conder
5 Day
opido
Befo
(n
2.
9.zation. †Presented as median (interquartile range).
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July 18, 2006:281–6 Clopidogrel and Coronary Artery Bypass SurgeryABG surgery, and, of these, nearly 90% have surgery
ithin 5 days of treatment, contrary to the ACC/AHA
uidelines recommendations. Our data also showed that the
erformance of CABG within 5 days of clopidogrel treatment
s associated with an increase in the proportion of patients
equiring blood transfusion and a greater number of packed
BC units transfused. We confirmed that rate of transfu-
ion requirement returned to normal (vs. rate of patients not
reated with clopidogrel) if surgery was delayed 5 days
fter clopidogrel was stopped, results similar to those
bserved in the CURE study (1,7). Thus, our data support
he ACC/AHA guidelines recommendations that encour-
ge the discontinuation of clopidogrel 5 days before
ABG to minimize the perioperative bleeding risk and the
eed for blood transfusion.
It could be hypothesized that the rush to early CABG is
elated to the high-risk features or unstable presenting
eatures of the patients. However, contrary to these expec-
ations, patients undergoing CABG within 5 days of clopi-
ogrel treatment did not differ significantly from those who
id not receive clopidogrel and underwent early CABG in
he presence of high-risk features, such as diabetes, previous
evascularization, prior stroke, and renal insufficiency, and
ith unstable presenting features, such as signs of conges-
ive heart failure, higher heart rate, and elevated cardiac
nzymes. This finding suggests that surgery was electively
erformed sooner than is recommended after the discontin-
ation of clopidogrel in the vast majority of patients. We did
ot collect information on the reasons for early or late
urgery in patients receiving clopidogrel and thus can only
peculate as to why this occurs. Higher-risk patients on
lopidogrel wait longer for CABG because physicians may
eed more time to discuss the risks with them and their
amilies, they may want the patients to be more stable before
urgery, or they may hope to provide the best milieu to
ower risk in these otherwise high-risk patients (i.e., by
aiting until the effect of clopidogrel is completely
one—5 days). In contrast, more stable patients may
eceive early CABG because of economic constraints and/or
essened concerns about bleeding with clopidogrel, espe-
ially with increasing experience among cardiac surgeons in
he management of patients on clopidogrel, meticulous
emostasis during surgery, and the use of platelet transfu-
ions and epsilon amino caproic acid or aprotinin in the
erioperative period.
Our analyses also better quantitate the magnitude of
ransfusion risks among those receiving clopidogrel and
arly surgery. Specifically, we found that although the
djusted odds for transfusion are approximately 36% higher,
he median absolute increase in total number of RBC units
ransfused was modest at one unit. Looked at another way,
he absolute proportion of patients receiving four or more
nits of RBC (a large bleed) was increased by 10% with
lopidogrel if surgery was performed within 5 days.
These data demonstrating a modest increase in transfu-
ion risk are generally lower than those seen in previous case teries (2–6). This lower risk may in part reflect a more stable
stimate of risks based on a much larger case sample in the
RUSADE Initiative. Alternatively, it is possible that as
urgeons and anesthesiologists gain experience with periop-
rative management of patients treated with clopidogrel,
isks have declined. This perioperative management could
nclude more liberal use of platelet transfusions (as seen in
ur study), the use of procoagulant and platelet-protective
rugs such as aprotinin and tranexamic acid, and closer
ttention to maintaining a dry surgical field prior to closure
4,12).
The use of GP IIb/IIIa antagonists was greater in
atients who received clopidogrel and underwent early
ABG. However, the relationship of clopidogrel with
leeding after CABG remained directionally and consis-
ently the same even when patients with GP IIb/IIIa were
xcluded and argues against significant confounding by GP
Ib/IIIa inhibitors.
The increase in bleeding observed in patients who re-
eived acute clopidogrel and CABG must be weighed
gainst the potential benefits of administering clopidogrel
hile awaiting surgery. Data from the CURE trial suggest
hat the use of clopidogrel in patients with NSTE ACS is
ssociated with very early effects on various outcome mea-
ures. Thus, the use of clopidogrel was associated with a
ower incidence of in-hospital events, including myocardial
nfarction (relative risk [RR], 0.60; 95% CI 0.48 to 0.76),
evere ischemia (RR, 0.74; 95% CI 0.61 to 0.90; p 0.003)
r recurrent angina (RR, 0.91; 95% CI 0.85 to 0.98; p 
.01) (1,7). Our observational study, however, was not able
o confirm these benefits because we did not have systematic
ostprocedural enzyme measurements or a rigorous clinical
rials event committee. Additionally, the benefits of delay-
ng CABG surgery for 5 days after the administration of
lopidogrel must be weighed against the potential risks of
vents while waiting as well as the economic consequences
f extended hospital length of stay.
tudy limitations. First, we considered the time between
ardiac catheterization and CABG surgery as a proxy for the
ime between the discontinuation of clopidogrel and CABG
ecause the exact time of discontinuation of clopidogrel
efore CABG was not available. Second, we did not collect
ata on the incidence of re-exploration after CABG, al-
hough this has been done in previous studies (2–6).
owever, consistent with previous studies, when we looked
t RBC transfusions requiring four or more units as a
urrogate for reoperation, the risk was higher among pa-
ients on clopidogrel undergoing early CABG compared
ith those undergoing early CABG but not receiving
lopidogrel. Third, serial hemoglobin values were not col-
ected in our dataset at the time of the initiation of the
RUSADE Initiative, and therefore we are unable to
rovide the actual values of hemoglobin/hematocrit that led
o transfusions. However, the similar levels of nadir hemat-
crit post-CABG in the four groups suggest that perhaps
he threshold for transfusion was not significantly different
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Clopidogrel and Coronary Artery Bypass Surgery July 18, 2006:281–6etween the four groups (median nadir hematocrit post-
ABG among patients who received any RBC transfusion-
lopidogrel/early CABG group 25.1 %, clopidogrel/late
ABG group 25.6%, no-clopidogrel/early CABG group
5.8%, and no-clopidogrel/late CABG group 25.9%). Per-
aps other factors besides nadir hematocrit may be impor-
ant in determining RBC transfusions, such as rate of
leeding or hemodynamic instability. Fourth, our compar-
sons of clinical outcomes by treatment strategy were obser-
ational. Although we adjusted all comparisons for baseline
linical factors, we cannot exclude any persistent unmea-
ured confounding. Nonetheless, because a randomized
linical trial evaluating the benefits and risks of patients
ndergoing early versus late CABG is unlikely to be
ndertaken as most physicians would consider this to be
nethical in view of data from the CURE trial (1,7), this
tudy is the first to provide insight into the scope of this
ssue at a national level.
onclusions. When CABG is required, the majority
87%) of patients treated with acute clopidogrel did not have
heir surgery delayed for the recommended 5-day interval,
ontrary to current ACC/AHA guidelines. These patients
emonstrated an increase in bleeding complications com-
ared with patients who did not receive clopidogrel and
nderwent early CABG. However, these bleeding risks
ust be weighed against the benefits of clopidogrel use
emonstrated in randomized clinical trials, as well as against
he economic impact of delaying CABG surgery.
eprint requests and correspondence: Dr. Rajendra H. Mehta,
ox 17969, Duke Clinical Research Institute, Durham, North
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